Get the Stockscreener App
1.99
1.00%
-0.02
Xenetic Biosciences Inc stock is traded at $1.99, with a volume of 17,528.
It is down -1.00% in the last 24 hours and down -9.13% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
See More
Previous Close:
$2.01
Open:
$1.98
24h Volume:
17,528
Relative Volume:
0.93
Market Cap:
$4.66M
Revenue:
$3.19M
Net Income/Loss:
$-2.23M
P/E Ratio:
-1.6188
EPS:
-1.2293
Net Cash Flow:
$-1.82M
1W Performance:
-6.57%
1M Performance:
-9.13%
6M Performance:
-44.10%
1Y Performance:
-54.67%
1-Day Range:
$1.92
$2.00
1-Week Range:
$1.885
$2.27
52-Week Range:
$1.87
$4.9392
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
1.99 | 4.66M | 3.19M | -2.23M | -1.82M | -1.2293 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Press Release Distribution & Media Outreach Platform for PR Agencies - ACCESS Newswire
Xenetic partner doses first patient in DNase CAR T-cell study - Investing.com India
Xenetic Biosciences doses first patient in DNase and CAR T-cell study - StreetInsider
Xenetic Biosciences, Inc. (XBIO) Stock Price, News, Quote & History - Yahoo Finance
Form 8K Xenetic Biosciences Inc For: 23 September - Investing.com India
Form 8K Xenetic Biosciences Inc For: 23 September By Investing.com - Investing.com UK
Santersus holders could own about 85% of the combined company in Xenetic Biosciences (XBIO)'s pending exchange. - Stock Titan
Xenetic to acquire Santersus in NET-targeting biotech combination - AllSci
Dig: Santersus Xenetic Sep MERGER premature — close ~Q4 2026 - Dealroom
Xenetic Biosciences (XBIO) investor reports 0% holding - Stock Titan
Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake - Yahoo Finance
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition - Benzinga
Xenetic Biosciences to Merge With Santersus in All-Stock Deal - Minichart
Form 8K Xenetic Biosciences Inc For: 16 September By Investing.com - Investing.com Nigeria
[SUPERSEDED by Dig 154759] Xenetic to merge with Santersus, ceding 85% of combined biotech to Swiss investors - Dealroom.co
Xenetic Biosciences to Acquire Santersus in All-Stock NET Therapeutics Deal - citybiz
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Xenetic Biosciences to acquire Santersus in all-stock deal By Investing.com - Investing.com Nigeria
Xenetic Biosciences to acquire Santersus in all-stock deal By Investing.com - Investing.com Australia
XBIO Looks 12.4% Overvalued on GF Value™ as Market Prices in Hig - GuruFocus
Form 8K Xenetic Biosciences Inc For: 16 September By Investing.com - Investing.com India
Form 8K Xenetic Biosciences Inc For: 16 September By Investing.com - Investing.com UK
Xenetic Biosciences to acquire Santersus in all-stock deal By Investing.com - Investing.com Canada
Xenetic Biosciences to acquire Santersus in all-stock deal - Investing.com
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics - ACCESS Newswire
Santersus deal would leave Xenetic Biosciences (NASDAQ: XBIO) owners with 15% - Stock Titan
Xenetic Biosciences, Inc. (NASDAQ:XBIO) To Acquire Santersus In All-Stock Deal - TradingView
A planned biotech deal would unite four clinical programs around one disease driver - Stock Titan
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition - Yahoo Finance
Xenetic Biosciences, Inc. (NASDAQ:XBIO) To Acquire Santersus in All-Stock Deal; New Ticker 'SNTS' Planned - TradingView
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics - Yahoo Finance
Xenetic Biosciences and Santersus AG agree to create a global leader in therapies against NETs - Demócrata
Xenetic Biosciences Inc. Warrants (XBIOW) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Xenetic Biosciences Inc. Warrants (XBIOW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Xenetic Biosciences Inc. Warrants (XBIOW) Peer Comparison – Compare with Others - Value Research
Xenetic Biosciences Inc. Warrants (XBIOW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Xenetic Biosciences, Inc. Revenue Breakdown – NASDAQ:XBIO - TradingView
XBIO Q2 2025 Earnings: Narrower-Than-Expected Loss of -$0.45 Beats Estimates by 31.07%Financial Health Score - vinanet.vn
Xenetic Biosciences Q2 royalty revenue rises on Takeda sublicense - TradingView
Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss - TradingView
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform - Yahoo Finance
Xenetic Biosciences: Q2 Earnings Snapshot - marketscreener.com
Xenetic Biosciences: Q2 Earnings Snapshot - AOL.com
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform - ACCESS Newswire
Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary - tradingview.com
Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary - TradingView
Xenetic Biosciences (XBIO) Rises 3.31% to $2.81, Approaching Key Resistance at $2.95TWAP Entry - dars.gov.et
Xenetic Biosciences (XBIO) Rises 3.31% to $2.81, Approaching Key Resistance at $2.95Earnings Quality Factor - vinanet.vn
XBIO Q2 2025 Earnings: Narrower Loss of $0.45 per Share Beats Estimates Despite No RevenueEarnings Surprise Stocks - vinanet.vn
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline - dars.gov.et
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):